Yunnan Baiyao

Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows

A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?

China's First Modified New Drug of Docetaxel Successfully Went to the US

Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021

On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.

Yunnan Baiyao: An Oriental Mystery in the Limelight (2/2)

Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.

Yunnan Baiyao: An Oriental Mystery in the Limelight (1/2)

Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.